A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes (COMET cohort)

May 28, 2026 updated by: The Affiliated Hospital of Hangzhou Normal University

Study on the Construction of Disease Cohort for Fatty Liver in the Elderly and Its Prevention and Treatment Strategies

To establish a cohort of elderly fatty liver disease based on the community medical examination population. Through the large-scale cohort study, the risk factors affecting fatty liver in the elderly will be explored in depth from the aspects of lifestyle, environment and genetics, the development pattern and mechanism of fatty liver in the elderly will be analysed, and the health risk assessment system and Chinese standard for fatty liver in the elderly covering cardiovascular risk, risk of hepatic fibrosis and risk of sarcopenia will be established, so as to provide the scientific basis for the precise intervention of fatty liver in the elderly in China.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

20000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310015
        • Recruiting
        • NO.518 Shangtang Road
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

elder people

Description

Inclusion Criteria:

  • ① Elderly people aged ≥65 years among permanent residents (living for more than 5 years) in the survey area;

    • Imaging diagnosis (ultrasound or FibroScan/FibroTouch) of fatty liver; -③ Voluntary participation in this study and signing an informed consent form.

Exclusion Criteria:

  • ①Major disability, mental illness, major wasting disease, severe cardiac, pulmonary and renal insufficiency;

    • Patients with combined primary liver cancer or other types of cancer; -③Patients who have received liver transplant or other organ transplants.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
control group
Observation Group
Lifestyle interventions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of liver fibrosis
Time Frame: 2 years
2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Incidence of cardiovascular disease
Time Frame: 2 years
2 years
Incidence of sarcopenia
Time Frame: 2 years
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Affiliated Hospital of Hangzhou Normal University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 12, 2026

Primary Completion (Estimated)

December 31, 2030

Study Completion (Estimated)

December 31, 2030

Study Registration Dates

First Submitted

November 17, 2025

First Submitted That Met QC Criteria

November 17, 2025

First Posted (Actual)

November 21, 2025

Study Record Updates

Last Update Posted (Actual)

June 1, 2026

Last Update Submitted That Met QC Criteria

May 28, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SJP20250401

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on NAFLD and NASH

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe